Amicus Therapeutics, Inc. (NASDAQ:FOLD) went up by 1.35% from its latest closing price when compared to the 1-year high value of $16.13 and move down -13.03%, while FOLD stocks collected 0.49% of gains with the last five trading sessions. Press Release reported on 08/10/20 that Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Worth an Investment?
Amicus Therapeutics, Inc. (NASDAQ: FOLD) The 36 Months beta value for FOLD stocks is at 1.17, while 9 of the analysts out of 11 who provided ratings for Amicus Therapeutics, Inc. stocks as a “buy” while 1 as overweight, 1 rated it as hold and 0 as sell. The average price we get from analysts is $20.09 which is $5.23 above current price. FOLD currently has a short float of 13.18% and public float of 231.75M with average trading volume of 2.60M shares.
FOLD Market Performance
FOLD stocks went up by 0.49% for the week, with the monthly drop of -3.52% and a quarterly performance of 11.40%, while its annual performance rate touched 52.78%. The simple moving average for the period of the last 20 days is -2.93% for FOLD stocks with the simple moving average of 22.93% for the last 200 days.
Analysts’ Opinion on Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Many brokerage firms have already submitted their reports for FOLD stocks, with BTIG Research repeating the rating for FOLD shares by setting it to “Buy”. The predicted price for FOLD socks in the upcoming period according to BTIG Research is $19 based on the research report published on June 17, 2020.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see FOLD stock at the price of $20, previously predicting the value of $19. The rating they have provided for FOLD stocks is “Overweight” according to the report published on February 4, 2020.
H.C. Wainwright gave “Buy” rating to FOLD stocks, setting the target price at $20 in the report published on November 12, 2019.
FOLD Stocks -4.78% Far from 50 Day Moving Average
After a stumble in the market that brought FOLD to its low price for the period of the last 52 weeks, Amicus Therapeutics, Inc. was unable to take a rebound, for now settling with -11.53% of loss for the given period.
The stock volatility was left at 3.66%, however, within the period of a single month, the volatility rate increased by 3.34%, while the shares sank at the distance of -5.50% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -8.29% lower at the present time.
In the course of the last 5 trading sessions, FOLD went up by +0.49%, which changed the moving average for the period of 200 days to the total of +49.03% of gains for the stock in comparison to the 20-day moving average settled at $14.66. In addition, Amicus Therapeutics, Inc. saw 46.51% in overturn over the period of a single year with a tendency to cut further gains.
FOLD Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Amicus Therapeutics, Inc. (FOLD), starting from WHITMAN BURKE W, who bought 1,500 shares at the price of $14.62 back on Sep 01. After this action, Rushing now owns 33,967 shares of Amicus Therapeutics, Inc., valued at $21,930 with the latest closing price.
Crowley John F, the Chairman & CEO of Amicus Therapeutics, Inc., sold 29,900 shares at the value of $14.18 during a trade that took place back on Sep 01, which means that Crowley John F is holding 850,813 shares at the value of $423,850 based on the most recent closing price.
FOLD Stock Fundamentals
The current profitability levels are settled at -165.03 for the present operating margin and +85.33 for gross margin. The net margin for Amicus Therapeutics, Inc. stands at -195.56. Total capital return value is set at -44.51, while invested capital returns managed to touch -53.03. Equity return holds the value -65.50%, with -36.90% for asset returns.
Based on Amicus Therapeutics, Inc. (FOLD), the company’s capital structure generated 44.13 points for debt to equity in total, while total debt to capital is set at the value of 30.62. Total debt to assets is settled at the value of 24.73 with long-term debt to equity ratio rests at -15.94 and long-term debt to capital is 42.62.
The value for Enterprise to Sales is 11.52 with debt to enterprise value settled at 0.10. The receivables turnover for Amicus Therapeutics, Inc. is 6.60 with the total asset turnover at the value of 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.04.